First-line Combination Treatment Based on Anlotinib
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to explore safety and therapeutic efficacy of anlotinib combined
with erlotinib/chemotherapy/IBI308 as first-line treatment in advanced NSCLC patients. The
primary endpoints of the study are safety and objective response rate (ORR);the secondary
endpoints are disease control rate (DCR), progression-free survival (PFS) and overall
survival (OS).